The safety of trastuzumab deruxtecan (T‐DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta‐analysis

In patients with BCBM, T-DXd-associated ILD/pneumonitis occurred in 10% of patient and frequently necessitated treatment modification. Although no fatal ILD was observed, the high discontinuation rate underscored the imperative for vigilant monitoring and protocol-guided management to mitigate pulmonary toxicity while preserving intracranial efficacy.